Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety
Violeta Jardin, General Manager at Haemoview Diagnostics, shared a post on LinkedIn about a recent article by Kaiki Oya et al, published in A and A Practice, adding:
“Tranexamic acid (TXA) is central to bleeding control in cardiac surgery, yet high cumulative dosing around cardiopulmonary bypass is linked to perioperative seizures and prolonged antifibrinolytic shutdown, particularly in patients with renal impairment.
This new case report of TXA-induced seizure immediately after CPB highlights the need for individualized TXA strategies and real-time assessment of its neuro- and haemostatic impact.
The ClotPro TPA-test offers the only viscoelastic quantification of TXA-induced inhibition of tPA-triggered fibrinolysis, allowing titration to effect rather than fixed dosing and supporting safer, lower-dose TXA regimens in high‑risk patients.
Yoshii et al. show that even a 1 g TXA bolus produces measurable, sustained antifibrinolytic activity, with TPA-test parameters closely tracking impaired eGFR—providing a practical tool to avoid TXA overdosing and balance bleeding, seizure, and thrombotic risk post‑cardiac surgery.”
Title: Tranexamic Acid-Induced Seizure After Cardiopulmonary Bypass: A Case Report
Authors: Kaiki Oya, Jun Maki, Midoriko Higashi
Read the Full Article on British Journal of Anaesthesia.
Title: Point-of-care testing for tranexamic acid efficacy: a proof-of-concept study in cardiac surgical patients
Authors: Ryogo Yoshii, Yuya Takahashi, Kenichi A. Tanaka, Hidetake Kawajiri, Teiji Sawa, Fumimasa Amaya, Satoru Ogawa
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
-
Jun 25, 2026, 15:23Jonas Kingo: ISTH 2026 in Paris Brings the Global Hemostasis Community Together
-
Jun 25, 2026, 15:21Balancing Therapeutic Progress and Emergency Preparedness in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Jun 25, 2026, 15:06Ifeanyichukwu Ifechidere: What If One of the Biggest Myth Fact About APS is Hidden in its Name?
-
Jun 25, 2026, 15:05Gopal Patidar: Advancing Haemovigilance and Global Collaboration at ISBT 2026
-
Jun 25, 2026, 14:34Heghine Khachatryan: Hemostasis at the Crossroads of Immunity and Inflammation